Serum I‐FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies
Alimentary Pharmacology & Therapeutics2013Vol. 37(4), pp. 482–490
Citations Over TimeTop 10% of 2013 papers
Marlou Adriaanse, Greetje J. Tack, Valéria Lima Passos, Jan Damoiseaux, Marco W.J. Schreurs, Kim van Wijck, Robert G. Riedl, Ad Masclee, Wim A. Buurman, Chris J. Mulder, Anita Vreugdenhil
Abstract
Enterocyte damage assessed by serum I-FABP correlates with the severity of villous atrophy in coeliac disease at the time of diagnosis. Although enterocyte damage improves upon treatment, substantial enterocyte damage persists despite absence of villous atrophy and low IgA-tTG levels in the majority of cases. Elevated I-FABP levels nonresponding to gluten-free diet are indicative of histological abnormalities and warrant further evaluation.
Related Papers
- → Coeliac disease: a biopsy is not always necessary for diagnosis(2008)213 cited
- → One Third of HLA DQ2 Homozygous Patients with Type 1 Diabetes Express Celiac Disease-Associated Transglutaminase Autoantibodies(1999)243 cited
- → The serum IgA class anti-tissue transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an international multi-centre study(2001)93 cited
- → Anti‐transglutaminase antibodies and coeliac disease(1999)24 cited
- → Tissue transglutaminase and endomysial autoantibodies measured in an historical cohort of children and young adults in whom coeliac disease was suspected(2002)9 cited